Cellular and viral determinants of the persistent HIV reservoir

持久性艾滋病毒储存库的细胞和病毒决定因素

基本信息

项目摘要

Eradication of the latent HIV reservoir remains the major stumbling block to achieving cure. To eliminate this reservoir, accurate definition (a biomarker) of latently infected cells of different types and within different tissues is highly needed. Several biomarkers proposed previously were able to very modestly enrich (~10-fold) for latently infected cells, but failed to capture the substantial portion of the latent reservoir. Without the detailed characterization of latently infected cells, identification of a suitable biomarker to capture the majority of the reservoir cells will remain challenging. Our long-term goal is to identify a biomarker of HIV latency that can be translated into strategies to target latently infected cells for elimination. The overall objectives of this application are to identify cellular and viral determinants of the persistent HIV reservoir and to test selected biomarkers for their ability to capture latently infected cells in vitro and ex vivo. Our central hypothesis is that a successful biomarker will be represented by reservoir determinants identified individually for cells of different phenotypes and states. The term “phenotype” refers to the canonical phenotypic subsets defined with widely used surface protein markers (for example, maturation phenotype – central memory; functional phenotype – T helper 17). The term “state” refers to a cell state more broadly defined by the cell's total transcriptomic signature: gene sets and pathways that are actively expressed. The rationale of the proposed research is the expected improvement in the efficiency of the reservoir capture when heterogeneity of the reservoir cells is taken into account. We will test our central hypothesis by pursuing the following specific aims: (1) Identify cellular determinants of different reservoir subsets and test selected biomarkers for cell enrichment in vitro; (2) Identify viral determinants of different reservoir subsets in vitro; (3) Validate the reservoir determinants and selected biomarkers using samples from people with HIV. To identify cellular and viral determinants of the persistent reservoir, latest innovations in RNA sequencing (RNA-Seq) technologies will be used. Single cell RNA-Seq coupled with immunophenotyping will be used to characterize the phenotypes and states of cells that can be infected with either CXCR4- or CCR5-tropic virus. Genes that can discriminate between latently infected and uninfected cells will be identified individually within each cell type. To inform on how the identified cellular determinants of the persistent reservoir relate to the type of provirus that they define, proviral activity in different cell types will be characterized using single cell RNA-Seq data, full length sequencing of HIV transcripts, and the PrimeFlow assay to quantify responsiveness of provirus to reactivation stimuli. Biomarkers will be selected from sets of cellular determinants of the HIV reservoir in different cell subsets. Antibodies against these proteins will be tested for the ability to efficiently capture the latently infected cells. Our ultimate goal is to ensure that identified biomarkers can accurately define latently infected cells in clinical samples, and specifically in different tissue compartments, where as much as 98% of the persistent reservoir resides in vivo. In collaboration with the Last Gift cohort, we will have a unique opportunity to conduct studies to validate the identified determinants and biomarkers using blood and lymphoid tissue samples from persons with HIV. When these studies are complete, we will have identified biomarkers that can be used to capture latently infected cells in vitro and ex vivo, with the efficiency of at least 500-fold greater than is currently achievable. These results will be significant because identified biomarkers can be used to isolate reservoir cells from different tissues to provide better characterization of the latent reservoir across the human body. In the future, these biomarkers can serve as a platform for development of strategies to target latently infected cells for elimination. Such research is important to address the needs of people living with HIV, including the large cohort of HIV- infected patients within the national VA Healthcare System.
根除潜伏的艾滋病毒储存库仍然是实现治愈的主要障碍。为了消除这个 储存库,不同类型和不同内部的潜伏感染细胞的准确定义(生物标志物) 非常需要纸巾。之前提出的几种生物标志物能够非常适度地富集(~10倍) 对于潜伏感染的细胞,但未能捕获潜伏病毒库的大部分。如果没有 潜伏感染细胞的详细特征,识别合适的生物标志物以捕获大多数 储存细胞的研究仍将具有挑战性。我们的长期目标是确定 HIV 潜伏期的生物标志物 可以转化为针对潜伏感染细胞进行消除的策略。本次活动的总体目标 应用是识别持久性 HIV 储存库的细胞和病毒决定因素并测试选定的 生物标志物能够在体外和离体捕获潜伏感染的细胞。我们的中心假设是 成功的生物标志物将由针对不同细胞单独识别的储存库决定因素来代表。 表型和状态。术语“表型”是指广泛定义的典型表型子集。 使用表面蛋白标记(例如,成熟表型 - 中央记忆;功能表型 - T 助手 17).术语“状态”是指由细胞的总转录组更广泛地定义的细胞状态 特征:活跃表达的基因集和途径。拟议研究的基本原理是 当储层细胞的异质性降低时,储层捕获效率的预期提高 考虑到。我们将通过追求以下具体目标来检验我们的中心假设:(1)确定 不同储库亚群的细胞决定因素并测试体外细胞富集的选定生物标志物; (2) 体外识别不同储存库亚群的病毒决定因素; (3) 验证储层决定因素 使用艾滋病毒感染者的样本选择生物标志物。确定细胞和病毒的决定因素 持久性储存库,将使用 RNA 测序 (RNA-Seq) 技术的最新创新。单细胞 RNA-Seq 与免疫表型分析相结合将用于表征细胞的表型和状态 可能感染 CXCR4 或 CCR5 病毒。可以潜在区分的基因 将在每种细胞类型中单独识别感染和未感染的细胞。告知如何识别 持久储存库的细胞决定因素与其定义的原病毒类型有关,原病毒活性 将使用单细胞 RNA-Seq 数据、HIV 全长测序来表征不同的细胞类型 转录本和 PrimeFlow 测定可量化原病毒对重新激活刺激的反应性。生物标志物 将从不同细胞亚群中的HIV储存库的细胞决定因素组中选择。抗体 将测试针对这些蛋白质的有效捕获潜伏感染细胞的能力。我们的终极 目标是确保已识别的生物标志物能够准确定义临床样本中的潜伏感染细胞,以及 特别是在不同的组织隔室中,其中 98% 的持久性储存库驻留在体内。 通过与“最后的礼物”队列合作,我们将有一个独特的机会进行研究来验证 使用艾滋病毒感染者的血液和淋巴组织样本确定了决定因素和生物标志物。什么时候 这些研究完成后,我们将确定可用于捕获潜伏感染的生物标志物 体外和离体细胞,其效率比目前可实现的至少高 500 倍。这些 结果将具有重要意义,因为已鉴定的生物标志物可用于从不同的细胞中分离出储存细胞。 组织,以更好地表征人体中的潜在储存库。未来,这些 生物标志物可以作为制定针对潜伏感染细胞进行消除的策略的平台。 此类研究对于满足艾滋病毒感染者(包括大批艾滋病毒感染者)的需求非常重要。 国家 VA 医疗系统内的感染患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nadejda S Beliakova-Bethell其他文献

Nadejda S Beliakova-Bethell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nadejda S Beliakova-Bethell', 18)}}的其他基金

The spectrum of long non-coding RNAs that regulate HIV expression and latency
调节 HIV 表达和潜伏期的长非编码 RNA 谱系
  • 批准号:
    10402718
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
The spectrum of long non-coding RNAs that regulate HIV expression and latency
调节 HIV 表达和潜伏期的长非编码 RNA 谱系
  • 批准号:
    10684324
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Cellular and viral determinants of the persistent HIV reservoir
持久性艾滋病毒储存库的细胞和病毒决定因素
  • 批准号:
    10251431
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Role of viral tropism in molecular signatures of HIV latency
病毒趋向性在 HIV 潜伏期分子特征中的作用
  • 批准号:
    10434386
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
HIV reactivation from latency - role of CD4 T cell maturation phenotype
HIV 从潜伏期重新激活 - CD4 T 细胞成熟表型的作用
  • 批准号:
    9323817
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
HIV reactivation from latency - role of CD4 T cell maturation phenotype
HIV 从潜伏期重新激活 - CD4 T 细胞成熟表型的作用
  • 批准号:
    9137251
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了